Chinese University of Hong Kong – Developmental Therapeutics Review – Q4 2010
Summary
Global Market Direct’s pharmaceuticals report, “Chinese University of Hong Kong – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.
Scope
Reasons to buy
Summary
Global Market Direct’s pharmaceuticals report, “Chinese University of Hong Kong – Developmental Therapeutics Review – Q4 2010” provides data on the institute’s research and development focus. The report includes information on therapeutics under development, complete with latest updates, and features on discontinued projects (if applicable).
This report is built using data and information sourced from Global Markets Direct’s proprietary databases, institute’s website, and featured press releases, both from institute and industry-specific third party sources, put together by Global Markets Direct’s team of industry experts.
Scope
- Review of therapeutics under development by Chinese University of Hong Kong.
- Overview of products under development across various therapy areas.
- Coverage of therapeutic molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Chinese University of Hong Kong with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of Chinese University of Hong Kong’s therapeutic products in the last quarter.
- Latest news and deals relating to the products.
Reasons to buy
- Identify new drug targets and therapeutic classes in Chinese University of Hong Kong’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying opportunities to fill portfolio gaps.
- Evaluate Chinese University of Hong Kong’s position with total access to a detailed information on its therapeutic products development.
- Assess the growth potential of Chinese University of Hong Kong in its therapy areas of focus.
- Exploit collaboration and partnership opportunities with Chinese University of Hong Kong.
- Avoid Intellectual Property Rights related issues.
Chinese University of Hong Kong Snapshot
Chinese University of Hong Kong Overview
Key Information
Key Facts
Chinese University of Hong Kong – Research and Development Overview
Key Therapeutic Areas
Chinese University of Hong Kong – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Chinese University of Hong Kong – Pipeline Products Glance
Chinese University of Hong Kong – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Chinese University of Hong Kong Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Chinese University of Hong Kong – Drug Profiles
Aliskiren for Immunoglobulin A Nephropathy
Product Description
Mechanism of Action
R&D Progress
Celecoxib
Product Description
Mechanism of Action
R&D Progress
Celecoxib + Famotidine
Product Description
Mechanism of Action
R&D Progress
Famotidine + Dologesics
Product Description
Mechanism of Action
R&D Progress
Fosamax
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Cisplatin for Nasopharyngeal Carcinoma (Chinese University of Hong Kong)
Product Description
Mechanism of Action
R&D Progress
Imipramine
Product Description
Mechanism of Action
R&D Progress
Magnesium Sulfate
Product Description
Mechanism of Action
R&D Progress
Naproxen
Product Description
Mechanism of Action
R&D Progress
Nexium
Product Description
Mechanism of Action
R&D Progress
Omeprazole
Product Description
Mechanism of Action
R&D Progress
Oseltamivir
Product Description
Mechanism of Action
R&D Progress
Paricalcitol
Product Description
Mechanism of Action
R&D Progress
Rabeprazole
Product Description
Mechanism of Action
R&D Progress
Simvastatin for Aneurysmal Subarachnoid Haemorrhage (Chinese University of Hong Kong)
Product Description
Mechanism of Action
R&D Progress
Zanamivir
Product Description
Mechanism of Action
R&D Progress
CUF2
Product Description
Mechanism of Action
R&D Progress
Curcumin + Ginkgo Extract
Product Description
Mechanism of Action
R&D Progress
Danggui Buxue Tang
Product Description
Mechanism of Action
R&D Progress
Danshen + Gegen
Product Description
Mechanism of Action
R&D Progress
Lingzhi + Sen Miao San
Product Description
Mechanism of Action
R&D Progress
Methotrexate + Infliximab
Product Description
Mechanism of Action
R&D Progress
Methotrexate + Infliximab
Product Description
Mechanism of Action
R&D Progress
Nexium
Product Description
Mechanism of Action
R&D Progress
Paracetamol + Ibuprofen
Product Description
Mechanism of Action
R&D Progress
Pegylated Interferon + Lamivudine
Product Description
Mechanism of Action
R&D Progress
Recombinant Epstein-Barr Virus (EBV) Vaccine
Product Description
Mechanism of Action
R&D Progress
Rituximab
Product Description
Mechanism of Action
R&D Progress
Rituximab + Cyclophosphamide
Product Description
Mechanism of Action
R&D Progress
Rosuvastatin
Product Description
Mechanism of Action
R&D Progress
Shi-Bi-Lin
Product Description
Mechanism of Action
R&D Progress
Traditional Chinese Medicine
Product Description
Mechanism of Action
R&D Progress
Chinese University of Hong Kong – Pipeline Analysis
Chinese University of Hong Kong – Pipeline Products by Therapeutic Class
Chinese University of Hong Kong Pipeline Products By Target
Chinese University of Hong Kong – Pipeline Products by Route of Administration
Chinese University of Hong Kong – Pipeline Products by Molecule Type
Chinese University of Hong Kong - Dormant Projects
Chinese University of Hong Kong – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jan 15, 2009: Traditional Chinese Medicine Effectively Relieves Irritable Bowel Syndrome
Feb 04, 2004: NIH Grants Bring CUHK's Research On Chinese Medicine To The International Arena
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Chinese University of Hong Kong – Pipeline by Therapy Area and Indication, 2010
Chinese University of Hong Kong – Pipeline by Stage of Development, 2010
Chinese University of Hong Kong – Monotherapy Products in Pipeline, 2010
Chinese University of Hong Kong – Combination Treatment Modalities in Pipeline, 2010
Chinese University of Hong Kong – Phase III, 2010
Chinese University of Hong Kong - Phase II, 2010
Chinese University of Hong Kong - Pipeline By Therapeutic Class, 2010
Chinese University of Hong Kong - Pipeline By Target, 2010
Chinese University of Hong Kong – Pipeline By Route of Administration, 2010
Chinese University of Hong Kong – Pipeline By Molecule Type, 2010
Chinese University of Hong Kong - Dormant Developmental Projects, 2010
Chinese University of Hong Kong, Other Locations 61
LIST OF FIGURES
Chinese University of Hong Kong – Pipeline by Therapy Area and Indication, 2010
Chinese University of Hong Kong – Pipeline by Stage of Development, 2010
Chinese University of Hong Kong – Monotherapy Products in Pipeline, 2010
Chinese University of Hong Kong – Combination Treatment Modalities in Pipeline, 2010
Chinese University of Hong Kong – Pipeline By Therapeutic Class, 2010
Chinese University of Hong Kong - Pipeline By Target, 2010
Chinese University of Hong Kong – Pipeline By Route of Administration, 2010
Chinese University of Hong Kong – Pipeline By Molecule Type, 2010 59
Chinese University of Hong Kong Overview
Key Information
Key Facts
Chinese University of Hong Kong – Research and Development Overview
Key Therapeutic Areas
Chinese University of Hong Kong – Pipeline Review
Pipeline Products by Stage of Development
Pipeline Products – Monotherapy
Pipeline Products – Combination Treatment Modalities
Chinese University of Hong Kong – Pipeline Products Glance
Chinese University of Hong Kong – Late Stage Pipeline
Phase III Products/Combination Treatment Modalities
Chinese University of Hong Kong Clinical Stage Pipeline Products
Phase II Products/Combination Treatment Modalities
Chinese University of Hong Kong – Drug Profiles
Aliskiren for Immunoglobulin A Nephropathy
Product Description
Mechanism of Action
R&D Progress
Celecoxib
Product Description
Mechanism of Action
R&D Progress
Celecoxib + Famotidine
Product Description
Mechanism of Action
R&D Progress
Famotidine + Dologesics
Product Description
Mechanism of Action
R&D Progress
Fosamax
Product Description
Mechanism of Action
R&D Progress
Gemcitabine + Cisplatin for Nasopharyngeal Carcinoma (Chinese University of Hong Kong)
Product Description
Mechanism of Action
R&D Progress
Imipramine
Product Description
Mechanism of Action
R&D Progress
Magnesium Sulfate
Product Description
Mechanism of Action
R&D Progress
Naproxen
Product Description
Mechanism of Action
R&D Progress
Nexium
Product Description
Mechanism of Action
R&D Progress
Omeprazole
Product Description
Mechanism of Action
R&D Progress
Oseltamivir
Product Description
Mechanism of Action
R&D Progress
Paricalcitol
Product Description
Mechanism of Action
R&D Progress
Rabeprazole
Product Description
Mechanism of Action
R&D Progress
Simvastatin for Aneurysmal Subarachnoid Haemorrhage (Chinese University of Hong Kong)
Product Description
Mechanism of Action
R&D Progress
Zanamivir
Product Description
Mechanism of Action
R&D Progress
CUF2
Product Description
Mechanism of Action
R&D Progress
Curcumin + Ginkgo Extract
Product Description
Mechanism of Action
R&D Progress
Danggui Buxue Tang
Product Description
Mechanism of Action
R&D Progress
Danshen + Gegen
Product Description
Mechanism of Action
R&D Progress
Lingzhi + Sen Miao San
Product Description
Mechanism of Action
R&D Progress
Methotrexate + Infliximab
Product Description
Mechanism of Action
R&D Progress
Methotrexate + Infliximab
Product Description
Mechanism of Action
R&D Progress
Nexium
Product Description
Mechanism of Action
R&D Progress
Paracetamol + Ibuprofen
Product Description
Mechanism of Action
R&D Progress
Pegylated Interferon + Lamivudine
Product Description
Mechanism of Action
R&D Progress
Recombinant Epstein-Barr Virus (EBV) Vaccine
Product Description
Mechanism of Action
R&D Progress
Rituximab
Product Description
Mechanism of Action
R&D Progress
Rituximab + Cyclophosphamide
Product Description
Mechanism of Action
R&D Progress
Rosuvastatin
Product Description
Mechanism of Action
R&D Progress
Shi-Bi-Lin
Product Description
Mechanism of Action
R&D Progress
Traditional Chinese Medicine
Product Description
Mechanism of Action
R&D Progress
Chinese University of Hong Kong – Pipeline Analysis
Chinese University of Hong Kong – Pipeline Products by Therapeutic Class
Chinese University of Hong Kong Pipeline Products By Target
Chinese University of Hong Kong – Pipeline Products by Route of Administration
Chinese University of Hong Kong – Pipeline Products by Molecule Type
Chinese University of Hong Kong - Dormant Projects
Chinese University of Hong Kong – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Recent Developments
Jan 15, 2009: Traditional Chinese Medicine Effectively Relieves Irritable Bowel Syndrome
Feb 04, 2004: NIH Grants Bring CUHK's Research On Chinese Medicine To The International Arena
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Chinese University of Hong Kong – Pipeline by Therapy Area and Indication, 2010
Chinese University of Hong Kong – Pipeline by Stage of Development, 2010
Chinese University of Hong Kong – Monotherapy Products in Pipeline, 2010
Chinese University of Hong Kong – Combination Treatment Modalities in Pipeline, 2010
Chinese University of Hong Kong – Phase III, 2010
Chinese University of Hong Kong - Phase II, 2010
Chinese University of Hong Kong - Pipeline By Therapeutic Class, 2010
Chinese University of Hong Kong - Pipeline By Target, 2010
Chinese University of Hong Kong – Pipeline By Route of Administration, 2010
Chinese University of Hong Kong – Pipeline By Molecule Type, 2010
Chinese University of Hong Kong - Dormant Developmental Projects, 2010
Chinese University of Hong Kong, Other Locations 61
LIST OF FIGURES
Chinese University of Hong Kong – Pipeline by Therapy Area and Indication, 2010
Chinese University of Hong Kong – Pipeline by Stage of Development, 2010
Chinese University of Hong Kong – Monotherapy Products in Pipeline, 2010
Chinese University of Hong Kong – Combination Treatment Modalities in Pipeline, 2010
Chinese University of Hong Kong – Pipeline By Therapeutic Class, 2010
Chinese University of Hong Kong - Pipeline By Target, 2010
Chinese University of Hong Kong – Pipeline By Route of Administration, 2010
Chinese University of Hong Kong – Pipeline By Molecule Type, 2010 59